| Bioactivity | Evofosfamide (TH-302) is a hypoxia-activated prodrug with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21% O2), respectively. | ||||||||||||
| Invitro | Evofosfamide (TH-302) induces γH2AX and apoptosis. Evofosfamide displays hypoxia-selective and concentration-dependent cytotoxic activity that is comparable in both p53-proficient and -deficient cells. Treatment with Evofosfamide (TH-302) alone causes an accumulation of G2/M cells. Inhibition of Chk1 by PF47736 in cells treated with Evofosfamide reduces Evofosfamide (TH-302)-mediated G2/M arrest under both normoxia and hypoxia[1]. | ||||||||||||
| Name | Evofosfamide | ||||||||||||
| CAS | 918633-87-1 | ||||||||||||
| Formula | C9H16Br2N5O4P | ||||||||||||
| Molar Mass | 449.04 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Evofosfamide
CAS: 918633-87-1 F: C9H16Br2N5O4P W: 449.04
Evofosfamide (TH-302) is a hypoxia-activated prodrug with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21%
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.